The University of Southampton
University of Southampton Institutional Repository

An advanced and detailed in vitro validation procedure for the radiolabeling of carrier-free terbutaline sulphate dry powder

An advanced and detailed in vitro validation procedure for the radiolabeling of carrier-free terbutaline sulphate dry powder
An advanced and detailed in vitro validation procedure for the radiolabeling of carrier-free terbutaline sulphate dry powder
The aerodynamic properties of 99mTc radiolabeled carrier-free terbutaline sulphate (TBS) have been thoroughly investigated following delivery by Turbuhaler® (AstraZeneca Lund, Sweden). A full and detailed radiolabeling procedure is also reported. The in vitro radiolabel validation was performed to determine whether TBS radiolabeled in this way would be representative of the commercially available product Bricanyl® Turbuhaler during clinical trials. The results indicated that variations in aerodynamic properties had been introduced and that the radiolabel would slightly underestimate the fine particle fraction of Bricanyl, but would nonetheless act as a suitable marker in vivo. Assumptions regarding the aerodynamic properties of doses likely to be received by clinical trial subjects were also examined. This has been achieved by extending the validation procedures beyond those usually reported to include dose number, time, and homogeneity dependent studies. It was found that doses extracted for testing purposes and simulated patient doses extracted shortly afterward had similar properties. Doses extracted 2 h after initial testing also had similar properties to the test doses. These results suggested that data from the test doses could be used for quality control purposes, would be representative of the doses to be received by clinical trial subjects, and that a short delay between initial testing and trial subject inhalation would be acceptable.
radiolabeling, pertechnetate, terbutaline, validation, dry powder lung deposition, turbuhaler, sulfate
227-236
Walker, Paul S.
d110682e-e70a-4afa-8042-3ec4f46428c3
Petterson, Gunilla L.
0b3589b8-684a-487d-a3d6-c6b7c4610931
Bondesson, Eva
ed20fdd1-cc5e-4189-8a79-87cfd4bd7091
Conway, Joy H.
bbe9a2e4-fb85-4d4a-a38c-0c1832c32d06
Walker, Paul S.
d110682e-e70a-4afa-8042-3ec4f46428c3
Petterson, Gunilla L.
0b3589b8-684a-487d-a3d6-c6b7c4610931
Bondesson, Eva
ed20fdd1-cc5e-4189-8a79-87cfd4bd7091
Conway, Joy H.
bbe9a2e4-fb85-4d4a-a38c-0c1832c32d06

Walker, Paul S., Petterson, Gunilla L., Bondesson, Eva and Conway, Joy H. (2001) An advanced and detailed in vitro validation procedure for the radiolabeling of carrier-free terbutaline sulphate dry powder. Journal of Aerosol Medicine, 14 (2), 227-236. (doi:10.1089/08942680152484153).

Record type: Article

Abstract

The aerodynamic properties of 99mTc radiolabeled carrier-free terbutaline sulphate (TBS) have been thoroughly investigated following delivery by Turbuhaler® (AstraZeneca Lund, Sweden). A full and detailed radiolabeling procedure is also reported. The in vitro radiolabel validation was performed to determine whether TBS radiolabeled in this way would be representative of the commercially available product Bricanyl® Turbuhaler during clinical trials. The results indicated that variations in aerodynamic properties had been introduced and that the radiolabel would slightly underestimate the fine particle fraction of Bricanyl, but would nonetheless act as a suitable marker in vivo. Assumptions regarding the aerodynamic properties of doses likely to be received by clinical trial subjects were also examined. This has been achieved by extending the validation procedures beyond those usually reported to include dose number, time, and homogeneity dependent studies. It was found that doses extracted for testing purposes and simulated patient doses extracted shortly afterward had similar properties. Doses extracted 2 h after initial testing also had similar properties to the test doses. These results suggested that data from the test doses could be used for quality control purposes, would be representative of the doses to be received by clinical trial subjects, and that a short delay between initial testing and trial subject inhalation would be acceptable.

Text
27468.pdf - Version of Record
Restricted to Repository staff only
Request a copy

More information

Published date: June 2001
Keywords: radiolabeling, pertechnetate, terbutaline, validation, dry powder lung deposition, turbuhaler, sulfate

Identifiers

Local EPrints ID: 27468
URI: http://eprints.soton.ac.uk/id/eprint/27468
PURE UUID: 5134d5f9-5a50-4300-81a8-29f265cdb53a
ORCID for Joy H. Conway: ORCID iD orcid.org/0000-0001-6464-1526

Catalogue record

Date deposited: 28 Apr 2006
Last modified: 11 Nov 2019 19:31

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×